RARE
Ultragenyx Pharmaceutical Inc
Price:  
49.48 
USD
Volume:  
454,394.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RARE EV/EBITDA

-336.9%
Upside

As of 2024-02-26, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,990.20 mil USD. RARE's TTM EBITDA according to its financial statements is -604.13 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 13.1x - 14.7x 14.2x
Forward P/E multiples 17.3x - 20.6x 17.9x
Fair Price (126.40) - (107.57) (117.20)
Upside -355.5% - -317.4% -336.9%
49.48 USD
Stock Price
(117.20) USD
Fair Price

RARE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-02-23 -6.70
2024-02-22 -6.62
2024-02-21 -6.52
2024-02-20 -6.48
2024-02-16 -6.62
2024-02-15 -6.26
2024-02-14 -6.18
2024-02-13 -5.95
2024-02-12 -6.33
2024-02-09 -6.33
2024-02-08 -6.15
2024-02-07 -6.05
2024-02-06 -6.21
2024-02-05 -6.06
2024-02-02 -5.82
2024-02-01 -5.97
2024-01-31 -5.97
2024-01-30 -6.08
2024-01-29 -6.23
2024-01-26 -6.09
2024-01-25 -6.13
2024-01-24 -5.90
2024-01-23 -6.02
2024-01-22 -6.04
2024-01-19 -6.04
2024-01-18 -5.84
2024-01-17 -5.88
2024-01-16 -5.96
2024-01-12 -6.19
2024-01-11 -6.25
2024-01-10 -6.38
2024-01-09 -6.54
2024-01-08 -6.74
2024-01-05 -6.44
2024-01-04 -6.37
2024-01-03 -6.49
2024-01-02 -6.52
2023-12-29 -6.47
2023-12-28 -6.53
2023-12-27 -6.66
2023-12-26 -6.45
2023-12-22 -6.43
2023-12-21 -6.16
2023-12-20 -6.14
2023-12-19 -6.53
2023-12-18 -6.18
2023-12-15 -6.22
2023-12-14 -6.21
2023-12-13 -6.06
2023-12-12 -5.88